SAN FRANCISCO — Drug makers are sick and tired of coming under attack for high prices.
And they’re spending tens of millions to try to make it stop.
“We’re under unprecedented pressure because there really is profound misunderstanding out there,” Acorda Therapeutics CEO Ron Cohen, who chairs the industry trade group Biotechnology Innovation Organization, told a crowd at BIO’s conference here this week.
About the Author Reprints
